{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:18:52Z","timestamp":1794586732233,"version":"4.9.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K10450"],"award-info":[{"award-number":["24K10450"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcyt.2026.102778","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:50:04Z","timestamp":1773215404000},"page":"102778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Manufacturing strategies for prolonged CAR-T cell persistence"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6506-2291","authenticated-orcid":false,"given":"Noriko","family":"Shimasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102778_bib0001","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0002","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0003","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0004","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102778_bib0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0006","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0007","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102778_bib0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102778_bib0009","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102778_bib0010","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0011","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41590-023-01538-6","article-title":"Human circulating and tissue-resident memory CD8(+) T cells","volume":"24","author":"Buggert","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0012","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0013","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0014","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","article-title":"CD8(+) T cell metabolism in infection and cancer","volume":"21","author":"Reina-Campos","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0015","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2322982122","article-title":"Regulation of CD45 isoforms during human effector and memory CD8 T cell differentiation: implications for T cell nomenclature","volume":"122","author":"McGuire","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2026.102778_bib0016","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri3298","article-title":"HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes","volume":"12","author":"Girard","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","article-title":"Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T panel","volume":"15","author":"Dulobdas","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2026.102778_bib0018","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102778_bib0019","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/s43018-025-00982-7","article-title":"Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure","volume":"6","author":"Hope","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jcyt.2026.102778_bib0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2026.102778_bib0021","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","volume":"31","author":"Locatelli","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0022","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0023","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"31","author":"Li","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0024","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2026.102778_bib0025","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0026","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.3390\/cancers14133168","article-title":"Umbilical cord blood as a source of less differentiated T cells to produce CD123 CAR-T cells","volume":"14","author":"Ca\u00ebl","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2026.102778_bib0027","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0028","first-page":"24","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jcyt.2026.102778_bib0029","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102778_bib0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102778_bib0031","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","article-title":"Regulatory T cells in the tumour microenvironment","volume":"25","author":"Imianowski","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jcyt.2026.102778_bib0032","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2249.2012.04657.x","article-title":"Suppression, subversion and escape: the role of regulatory T cells in cancer progression","volume":"171","author":"Oleinika","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0033","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbmt.2006.01.005","article-title":"Isolation of CD4+CD25+ regulatory T cells for clinical trials","volume":"12","author":"Hoffmann","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102778_bib0034","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2026.102778_bib0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0036","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jcyt.2026.102778_bib0037","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2026.102778_bib0038","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102778_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000990","article-title":"Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources","volume":"8","author":"Schmidts","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102778_bib0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jcyt.2026.102778_bib0041","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020105220","article-title":"IL-2\/IL-7-inducible factors pioneer the path to T cell differentiation in advance of lineage-defining factors","volume":"39","author":"Bevington","year":"2020","journal-title":"Embo J"},{"key":"10.1016\/j.jcyt.2026.102778_bib0042","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","article-title":"IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients","volume":"107","author":"Ahmadzadeh","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102778_bib0043","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/80868","article-title":"Interleukin-7 mediates the homeostasis of na\u00efve and memory CD8 T cells in vivo","volume":"1","author":"Schluns","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0044","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2026.102778_bib0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102778_bib0046","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102778_bib0047","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CJI.0000000000000229","article-title":"Adoptive transfer of interleukin-21-stimulated human CD8+ T memory stem cells efficiently inhibits tumor growth","volume":"41","author":"Chen","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2026.102778_bib0048","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1073\/pnas.83.10.3194","article-title":"Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells","volume":"83","author":"Yu","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2026.102778_bib0049","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jcyt.2026.102778_bib0051","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102778_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","volume":"31","author":"Kitte","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2026.102778_bib0053","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0054","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102778_bib0055","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1172\/JCI133215","article-title":"Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability","volume":"130","author":"Guedan","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2026.102778_bib0056","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0057","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1126\/science.abq0225","article-title":"Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning","volume":"378","author":"Daniels","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102778_bib0058","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102778_bib0059","doi-asserted-by":"crossref","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102778_bib0060","article-title":"Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization","volume":"5","author":"Leung","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2026.102778_bib0061","doi-asserted-by":"crossref","first-page":"eabb6295","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0062","doi-asserted-by":"crossref","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0063","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102778_bib0064","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41586-025-09507-9","article-title":"Systematic discovery of CRISPR-boosted CAR T cell immunotherapies","volume":"646","author":"Datlinger","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102778_bib0065","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102778_bib0066","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jcyt.2026.102778_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101570","article-title":"Effects of CRISPR-Cas9-mediated FOXP3 knockout on CAR T cell potency","volume":"33","author":"Peter","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2026.102778_bib0068","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s43018-025-01009-x","article-title":"CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuit","volume":"6","author":"Yi","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jcyt.2026.102778_bib0069","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","article-title":"RASA2 ablation in T cells boosts antigen sensitivity and long-term function","volume":"609","author":"Carnevale","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102778_bib0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41467-022-35583-w","article-title":"Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy","volume":"14","author":"Trefny","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102778_bib0071","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","article-title":"TET2 guards against unchecked BATF3-induced CAR T cell expansion","volume":"615","author":"Jain","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102778_bib0072","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood.2021012714","article-title":"Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy","volume":"139","author":"Yoshikawa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102778_bib0073","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0074","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00281-024-01019-4","article-title":"Advances in manufacturing chimeric antigen receptor immune cell therapies","volume":"46","author":"Ramamurthy","year":"2024","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176618","article-title":"Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: a narrative review","volume":"974","author":"Boretti","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0076","article-title":"Toward rapid, widely available autologous CAR-T cell therapy\u2014artificial intelligence and automation enabling the smart manufacturing hospital","volume":"9","author":"Hort","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jcyt.2026.102778_bib0077","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s42255-020-0256-z","article-title":"Metabolic conditioning of CD8(+) effector T cells for adoptive cell therapy","volume":"2","author":"Klein Geltink","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.jcyt.2026.102778_bib0078","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s42255-024-00976-2","article-title":"Metabolic engineering for optimized CAR-T cell therapy","volume":"6","author":"McPhedran","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.jcyt.2026.102778_bib0079","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0080","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/0008-5472.CAN-16-1925","article-title":"Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-\u03b4 inhibition","volume":"77","author":"Abu Eid","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102778_bib0081","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102778_bib0082","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007002","article-title":"AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival","volume":"11","author":"Mehra","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102778_bib0083","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95103","article-title":"Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy","volume":"2","author":"Klebanoff","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2026.102778_bib0084","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-21-0452","article-title":"Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells","volume":"27","author":"Nian","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102778_bib0085","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102778_bib0086","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","article-title":"MEK inhibition reprograms CD8(+) T lymphocytes into memory stem cells with potent antitumor effects","volume":"22","author":"Verma","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0087","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102778_bib0088","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102778_bib0089","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nm.1982","article-title":"Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.20892\/j.issn.2095-3941.2018.0118","article-title":"Memory stem T cells generated by Wnt signaling from blood of human renal clear cell carcinoma patients","volume":"16","author":"Yan","year":"2019","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0091","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102778_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcyt.2026.102778_bib0093","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.stem.2024.10.004","article-title":"Maturation and persistence of CAR T cells derived from human pluripotent stem cells via chemical inhibition of G9a\/GLP","volume":"32","author":"Jing","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2026.102778_bib0094","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102778_bib0095","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2026.102778_bib0096","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102778_bib0097","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41375-025-02518-5","article-title":"Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T\u00ae Chimeric Antigen Receptor (CAR) T cell therapy CC-98633\/BMS-986354 in participants with triple-class exposed multiple myeloma","volume":"39","author":"Ravi","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102778_bib0098","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2026.102778_bib0099","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2026.102778_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1183698","article-title":"CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes","volume":"14","author":"Kapitza","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102778_bib0101","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102778_bib0102","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41467-025-59298-w","article-title":"Two-stage CD8(+) CAR T-cell differentiation in patients with large B-cell lymphoma","volume":"16","author":"Cao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102778_bib0103","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1158\/1078-0432.CCR-10-1499","article-title":"Stem cell quiescence","volume":"17","author":"Li","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:25:59Z","timestamp":1783337159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926007395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":103,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1465324926007395"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102778","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manufacturing strategies for prolonged CAR-T cell persistence","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102778"}}